WTX-124

P1, N=150, Recruiting, Werewolf Therapeutics, Inc. | Trial completion date: Jul 2025 --> Jul 2026 | Trial primary completion date: Jul 2025 --> Jul 2026

P1, N=150, Recruiting, Werewolf Therapeutics, Inc.

Mechanistically, WTX-124 treatment triggered the activation of T cells and natural killer cells, and markedly shifted the immune activation profile of the tumor microenvironment, resulting in significant inhibition of tumor growth in syngeneic tumor models. Collectively, these data demonstrate that WTX-124 minimizes the toxicity of IL-2 treatment in the periphery while retaining the full pharmacology of IL-2 in the tumor microenvironment, supporting its further development as a cancer immunotherapy treatment.

WTX 124 also demonstrated favorable pharmacokinetic and tolerability characteristics in cynomolgus monkeys resulting in minimal release of IL-2 in the periphery. Conclusions The combination of tumor-selective activation of WTX-124 with reduced peripheral toxicities and its favorable pharmacokinetic profile supports moving this compound into clinical development.

In vitro proteolytic activation by human tumor samples will also be presented. The tumor-selective activation of WTX-124 with reduced peripheral toxicities supports its further clinical development.